Literature DB >> 15887864

Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR.

E Resmini1, G Murialdo, M Giusti, M Boschetti, F Minuto, D Ferone.   

Abstract

We describe the case of an acromegalic patient primarily treated with octreotide LAR in whom the pituitary tumor disappeared after 18 months of treatment. A 68-yr-old woman, with clinical suspicion of acromegaly, was admitted to our Unit with the ultrasonographical evidence of cardiac hypertrophy, arrhythmias, right branch block and interatrial septum aneurism. She referred hands and feet enlargement since the age of 30 and facial disfigurements since the age of 50. At the age of 45 she underwent surgery for carpal tunnel syndrome and at the age of 61 an euthyroid nodular goiter was diagnosed. Hormonal evaluation showed elevated circulating GH levels (25+/-3.2 ng/ml), not suppressible after oral glucose load, and elevated IGF-I levels (646 ng/ml), whereas the remaining pituitary function was normal. Visual perimetry was normal, whereas magnetic resonance imaging (MRI) showed an intrasellar pituitary adenoma with maximal diameter of 9 mm. In order to improve cardiovascular function before surgery, the patient started octreotide LAR 20 mg every 4 weeks for 3 months. Then based on IGF-I values, the dose was adjusted to 30 mg. After 6 months a second MRI showed significant tumor reduction (>50% of baseline maximal diameter), GH and IGF-I were within the normal range and the patient continued the treatment. After one-year therapy, an improvement of cardiac alterations was recorded and the patient was referred to the neurosurgeon. However, she refused the operation. At 18-month follow-up, MRI showed the complete disappearance of direct and indirect signs of pituitary adenoma. To our knowledge, this is the first case of complete radiological remission of pituitary tumor during octreotide LAR treatment in acromegaly.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15887864     DOI: 10.1007/bf03345361

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  14 in total

Review 1.  Criteria for cure of acromegaly: a consensus statement.

Authors:  A Giustina; A Barkan; F F Casanueva; F Cavagnini; L Frohman; K Ho; J Veldhuis; J Wass; K Von Werder; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  2000-02       Impact factor: 5.958

2.  Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.

Authors:  A J van der Lely ; A Muller; J A Janssen; R J Davis; K A Zib; J A Scarlett; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

3.  Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.

Authors:  Giovanni Amato; Gherardo Mazziotti; Mario Rotondi; Sergio Iorio; Mauro Doga; Francesca Sorvillo; Giovanni Manganella; Francesco Di Salle; Andrea Giustina; Carlo Carella
Journal:  Clin Endocrinol (Oxf)       Date:  2002-01       Impact factor: 3.478

4.  Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum.

Authors:  W H Daughaday; I K Mariz; S L Blethen
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

5.  Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.

Authors:  A Colao; D Ferone; P Marzullo; P Cappabianca; S Cirillo; V Boerlin; I Lancranjan; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

6.  Improvement of acromegaly after octreotide LAR treatment.

Authors:  Ruth Mangupli; Aponte Lisette; Contreras Ivett; Camperos Paul; Cruz de los Ríos Victoria; Cevallos Jose Luis
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 7.  Systemic complications of acromegaly: epidemiology, pathogenesis, and management.

Authors:  Annamaria Colao; Diego Ferone; Paolo Marzullo; Gaetano Lombardi
Journal:  Endocr Rev       Date:  2004-02       Impact factor: 19.871

Review 8.  Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.

Authors:  Kate McKeage; Susan Cheer; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Scalp hair loss caused by octreotide in a patient with acromegaly: a case report.

Authors:  Y Nakauchi; Y Kumon; H Yamasaki; K Tahara; M Kurisaka; K Hashimoto
Journal:  Endocr J       Date:  1995-06       Impact factor: 2.349

Review 10.  Medical treatment in acromegaly.

Authors:  Angela N Paisley; Peter J Trainer
Journal:  Curr Opin Pharmacol       Date:  2003-12       Impact factor: 5.547

View more
  2 in total

1.  Active postoperative acromegaly: sustained remission after discontinuation of somatostatin analogues.

Authors:  Cristina Alvarez-Escola; Jersy Cardenas-Salas
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2016-11-21

2.  Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.

Authors:  Kiyoe Kurahashi; Itsuro Endo; Takeshi Kondo; Kana Morimoto; Sumiko Yoshida; Akio Kuroda; Ken-Ichi Aihara; Munehide Matsuhisa; Kohei Nakajima; Yoshifumi Mizobuchi; Shinji Nagahiro; Masahiro Abe; Seiji Fukumoto
Journal:  Intern Med       Date:  2017-08-21       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.